Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Life Sciences Industry Analysis

UpdatedAug 26, 2025
DataAggregated Company Financials
Companies63
  • 7D-0.5%
  • 3M15.3%
  • 1Y-20.2%
  • YTD-9.1%

Over the last 7 days, the Life Sciences industry has remained flat. Unfortunately though, the industry is down 20% over the past 12 months. As for the next few years, earnings are expected to grow by 14% per annum.

Industry Valuation and Performance

Has the U.S. Life Sciences Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Tue, 26 Aug 2025US$588.7bUS$144.1bUS$14.5b29x40.6x4.1x
Thu, 24 Jul 2025US$540.0bUS$143.4bUS$8.7b37.3x62.2x3.8x
Sat, 21 Jun 2025US$516.2bUS$142.9bUS$9.2b35.3x56.3x3.6x
Mon, 19 May 2025US$519.4bUS$142.7bUS$9.1b33.3x57.1x3.6x
Wed, 16 Apr 2025US$525.4bUS$142.6bUS$10.0b34.8x52.8x3.7x
Fri, 14 Mar 2025US$587.4bUS$143.1bUS$9.8b37.4x60.2x4.1x
Sun, 09 Feb 2025US$658.3bUS$143.1bUS$11.1b38.1x59.3x4.6x
Tue, 07 Jan 2025US$665.5bUS$142.4bUS$10.2b43.7x65.2x4.7x
Thu, 05 Dec 2024US$673.5bUS$142.4bUS$10.2b44.4x65.9x4.7x
Sat, 02 Nov 2024US$672.6bUS$142.2bUS$8.9b39.1x75.4x4.7x
Mon, 30 Sep 2024US$748.6bUS$141.8bUS$8.5b40.1x88.1x5.3x
Wed, 28 Aug 2024US$740.9bUS$141.8bUS$8.5b37.8x87.2x5.2x
Fri, 26 Jul 2024US$709.8bUS$141.1bUS$12.5b36.3x56.7x5x
Sun, 23 Jun 2024US$694.3bUS$141.3bUS$12.2b38.6x57x4.9x
Tue, 21 May 2024US$741.0bUS$141.5bUS$12.4b38.6x59.6x5.2x
Thu, 18 Apr 2024US$690.2bUS$142.0bUS$12.8b41.9x54x4.9x
Sat, 16 Mar 2024US$745.1bUS$142.1bUS$12.8b43.9x58x5.2x
Mon, 12 Feb 2024US$708.4bUS$141.9bUS$12.7b39.7x55.7x5x
Wed, 10 Jan 2024US$692.8bUS$153.8bUS$14.2b36.3x48.9x4.5x
Fri, 08 Dec 2023US$648.0bUS$153.7bUS$14.0b35.2x46.3x4.2x
Sun, 05 Nov 2023US$597.4bUS$153.9bUS$11.0b31.5x54.2x3.9x
Tue, 03 Oct 2023US$672.6bUS$154.6bUS$11.2b32.9x60x4.4x
Thu, 31 Aug 2023US$736.8bUS$154.6bUS$11.2b33.5x65.7x4.8x
Sat, 29 Jul 2023US$734.3bUS$154.7bUS$11.6b31.5x63.2x4.7x
Mon, 26 Jun 2023US$690.9bUS$152.4bUS$12.5b29.3x55.3x4.5x
Wed, 24 May 2023US$684.3bUS$152.1bUS$12.5b29x54.9x4.5x
Fri, 21 Apr 2023US$718.9bUS$154.6bUS$10.8b29.4x66.5x4.7x
Sun, 19 Mar 2023US$701.0bUS$154.5bUS$10.8b27.3x64.8x4.5x
Tue, 14 Feb 2023US$755.9bUS$155.6bUS$8.7b31.3x86.8x4.9x
Thu, 12 Jan 2023US$762.7bUS$155.3bUS$8.5b30.5x89.5x4.9x
Sat, 10 Dec 2022US$761.9bUS$155.1bUS$8.8b28.4x86.8x4.9x
Mon, 07 Nov 2022US$707.3bUS$154.9bUS$9.1b25.8x78x4.6x
Wed, 05 Oct 2022US$750.3bUS$152.5bUS$17.0b24.5x44.1x4.9x
Fri, 02 Sep 2022US$763.7bUS$152.2bUS$17.3b29.2x44.1x5x
Price to Earnings Ratio

44.1x


Total Market Cap: US$763.7bTotal Earnings: US$17.3bTotal Revenue: US$152.2bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Life Sciences Industry Price to Earnings3Y Average 61.9x202320242025
Current Industry PE
  • Investors are pessimistic on the American Life Sciences industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 40.6x which is lower than its 3-year average PE of 61.9x.
  • The 3-year average PS ratio of 4.6x is higher than the industry's current PS ratio of 4.1x.
Past Earnings Growth
  • The earnings for companies in the Life Sciences industry have declined 5.7% per year over the last three years.
  • Meanwhile revenues have remained mostly flat.
  • This means that although sales have remained flat, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market0.19%
Healthcare-0.34%
Life Sciences-0.46%
Clinical Research and Equipment-0.46%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
TMO Thermo Fisher ScientificUS$490.750.7%
+US$1.2b		-19.0%PE28.1x
TECH Bio-TechneUS$56.716.4%
+US$467.1m		-20.5%PE120.2x
CRL Charles River Laboratories InternationalUS$164.113.6%
+US$277.1m		-19.3%PS2x
BIO Bio-Rad LaboratoriesUS$297.373.1%
+US$243.6m		-6.9%PE25.2x
SHC Sotera HealthUS$16.393.7%
+US$167.6m		4.9%PE194.3x

Latest News

SHC
US$16.39
Sotera Health
7D
3.7%
1Y
4.9%
AVTR
US$13.21
Avantor
7D
1.8%
1Y
-48.4%
TEM
US$75.90
Tempus AI
7D
-3.3%
1Y
25.4%
MEDP
US$466.80
Medpace Holdings
7D
0.8%
1Y
21.2%
TMO
US$490.75
Thermo Fisher Scientific
7D
0.7%
1Y
-19.0%
A
US$119.15
Agilent Technologies
7D
-0.8%
1Y
-15.6%
ICLR
US$171.75
ICON
7D
-3.8%
1Y
-46.8%

After Leaping 25% ICON Public Limited Company (NASDAQ:ICLR) Shares Are Not Flying Under The Radar

Aug 20
After Leaping 25% ICON Public Limited Company (NASDAQ:ICLR) Shares Are Not Flying Under The Radar
MTD
US$1,289.78
Mettler-Toledo International
7D
-2.5%
1Y
-9.3%
DHR
US$207.73
Danaher
7D
-2.1%
1Y
-22.7%
TECH
US$56.71
Bio-Techne
7D
6.4%
1Y
-20.5%
ILMN
US$99.66
Illumina
7D
-0.9%
1Y
-23.6%

Illumina (NASDAQ:ILMN) Strong Profits May Be Masking Some Underlying Issues

Aug 08
Illumina (NASDAQ:ILMN) Strong Profits May Be Masking Some Underlying Issues
FTRE
US$8.86
Fortrea Holdings
7D
11.9%
1Y
-60.6%

Global Demographic Trends Will Spur Clinical Advances

Fortrea Holdings’ price target has been revised upward to $7.02, primarily due to solid earnings visibility and positive physician survey results for hospital segments, despite cost challenges in managed care and a neutral outlook in clinical laboratories. Analyst Commentary Earnings visibility remains solid for hospital-focused segments.
CRL
US$164.11
Charles River Laboratories International
7D
3.6%
1Y
-19.3%
BIO
US$297.37
Bio-Rad Laboratories
7D
3.1%
1Y
-6.9%

Analysts Are Updating Their Bio-Rad Laboratories, Inc. (NYSE:BIO) Estimates After Its Second-Quarter Results

Aug 03
Analysts Are Updating Their Bio-Rad Laboratories, Inc. (NYSE:BIO) Estimates After Its Second-Quarter Results
RGEN
US$121.26
Repligen
7D
-2.3%
1Y
-17.3%
IQV
US$188.02
IQVIA Holdings
7D
-2.3%
1Y
-24.4%